Which of the following is NOT included in patient preparation for Sr-89 chloride therapy?

In the context of preparing a patient for Sr-89 chloride therapy, the focus is on ensuring that the patient is optimally prepared for the treatment while minimizing any potential risks. Sr-89 chloride is a radiopharmaceutical used primarily for pain relief in patients with bone metastases.

The process usually involves several critical assessments and preparations. For instance, nuclear medicine bone imaging is often conducted to evaluate the extent of bone involvement by metastases, which aids in planning the patient's treatment. A complete blood count is essential to assess the patient's overall health and determine if there are any hematological concerns that could affect treatment.

Renal function studies are important as well, especially since the kidneys are responsible for filtering radiopharmaceutical agents from the bloodstream. Ensuring that the kidneys are functioning appropriately helps prevent possible complications from the therapy.

Discontinuation of pain medication is not generally required or included in patient preparation for Sr-89 therapy. In fact, patients may continue to take pain medications as necessary to manage their symptoms. This approach helps maintain the patient’s comfort and quality of life while undergoing treatment. Therefore, the aspect that does not generally apply to the standard preparation for this therapy is the discontinuation of pain medication.